Ladenburg raised the firm’s price target on Vericel (VCEL) to $56 from $54 and keeps a Buy rating on the shares. The company delivered strong Q3 results, marked by record revenue, substantial margin expansion, and key regulatory advancements, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.